Ethnicity and Pain Reviewed

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ALBUQUERQUE-"Ethnicity is a relatively understudied concept in pain medicine," David B. Morris, PhD, writes in his review of ethnicity and pain (Pain Clinical Updates vol. IX, no. 4, November 2001). Existing research, he said, has provided "few firm generalizations" about the relationship between ethnicity and pain. This is due, in part, to the fact that both pain and ethnicity are "multidimensional, malleable, and shaped by culture."

ALBUQUERQUE—"Ethnicity is a relatively understudied concept in pain medicine," David B. Morris, PhD, writes in his review of ethnicity and pain (Pain Clinical Updates vol. IX, no. 4, November 2001). Existing research, he said, has provided "few firm generalizations" about the relationship between ethnicity and pain. This is due, in part, to the fact that both pain and ethnicity are "multidimensional, malleable, and shaped by culture."

Some studies suggest that minorities are less likely to receive adequate treatment for pain. Dr. Morris pointed to a US study that found no differences in the amount of opioid self-administered for acute pain among different ethnic groups, but significant differences in the amount of opioid prescribed.

Even when the prescription is adequate, he noted, "ethnic groups face inequalities that translate into poorly controlled pain." For example, pharmacies in poor, nonwhite neighborhoods may not stock adequate supplies of opioids.

Finally, Dr. Morris emphasized that although there may be measurable differences in how different ethnic groups experience pain, there are also "deep similarities." Studies of specific conditions, from cancer to childbirth, have found "major similarities among various ethnocultural groups in pain perception and response," he said.

Recent Videos
Genetic consultation and next-generation sequencing can also complement treatment strategies for patients with pancreatic cancer.
Brett L. Ecker, MD, focused on the use of de-escalation therapy, which is gaining momentum in neuroendocrine tumors.
Immunotherapy options like CAR T-cell therapy and antigen-presenting cell-directed agents are currently being evaluated in the pancreatic cancer field.
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Pancreatic cancer is projected to become the second-leading cause of cancer-related deaths by 2030 in the United States.
2 experts are featured in this video
2 experts are featured in this video
2 experts are featured in this video
4 KOLs are featured in this series.
Related Content